We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ovarian cancer drug

News List

AstraZeneca’s ovarian cancer drug Olaparib gets NICE approval pharmaceutical-technology
July 30, 2019
AstraZeneca has obtained the National Institute for Health and Care Excellence (NICE) approval for use of its olaparib drug as a first-line maintenance therapy to treat gynaecological cancers patients on the National Health Service (NHS) in England, UK.
AZ/Merck & Co get new US use for ovarian cancer drug pharmaphorum
December 21, 2018
After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and a first approval in China for its new anaemia drug.
Scientists identify cause of resistance to breast and ovarian cancer drug europeanpharmaceuticalreview
May 11, 2018
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors…
Precision ovarian cancer drug shows early promise pharmatimes
June 06, 2017
An experimental targeted treatment for ovarian cancer has shown promise in early clinical trials shrinking tumours in half of women with the disease.